Discovery in mass tort litigation typically takes anywhere from six months to several years, with the entire case timeline spanning two to five years from filing to final settlement. There is no standard timeline””some cases resolve relatively quickly while others drag on for more than a decade. The Hair Relaxer MDL, for instance, has a bellwether discovery completion deadline of February 16, 2026, roughly two years after the litigation consolidated, while the Depo-Provera MDL’s discovery phase is scheduled to conclude in approximately six months. These variations reflect the inherent unpredictability of complex multi-plaintiff litigation.
The discovery phase is often the longest and most resource-intensive part of mass tort cases because it involves gathering evidence from potentially thousands of plaintiffs and reviewing millions of corporate documents. In the 3M Combat Arms Earplug MDL, which involved nearly 260,000 plaintiffs and eventually settled for $6.01 billion in 2023, the discovery process spanned several years before the parties could even approach resolution. For plaintiffs waiting on compensation, understanding these timelines is essential for setting realistic expectations. This article examines the specific factors that influence discovery length, provides current examples from active MDLs, explains the bellwether trial process, and offers practical insight into what claimants can expect at each stage of mass tort litigation.
Table of Contents
- What Determines How Long Discovery Takes in Mass Tort Cases?
- The Bellwether Selection Process and Its Impact on Discovery Timelines
- Current MDL Discovery Schedules: A Comparative Analysis
- What Claimants Should Expect During the Discovery Phase
- Common Delays and Obstacles in Mass Tort Discovery
- Post-Settlement Timelines and Final Resolution
- Looking Ahead: Mass Tort Discovery in an Evolving Legal Landscape
- Conclusion
What Determines How Long Discovery Takes in Mass Tort Cases?
The length of discovery in mass tort litigation depends on several interconnected factors, with the number of plaintiffs being among the most significant. When an MDL involves tens of thousands or even hundreds of thousands of claimants, courts must establish procedures for managing case-specific discovery at scale. The Uber Sexual Assault MDL demonstrates a more compressed timeline, with case-specific fact discovery for bellwether cases due by July 16, 2025, and the first trial scheduled for December 8, 2025. This relatively rapid pace reflects a smaller plaintiff pool compared to pharmaceutical or medical device MDLs. Case complexity also drives discovery duration.
Medical and scientific evidence requires extensive expert testimony, and defendants in pharmaceutical cases often possess millions of internal documents that must be reviewed, categorized, and potentially produced. The GLP-1 (Ozempic) MDL has scheduled an evidentiary hearing for May 2025, with the first bellwether trial set for January 12, 2026″”a timeline shaped by the need to establish causation between the medication and alleged injuries through detailed scientific analysis. Corporate document volume presents a particular challenge. Large pharmaceutical and medical device companies maintain decades of research data, internal communications, regulatory submissions, and marketing materials. Reviewing this evidence for relevance and privilege can consume months of attorney time before substantive depositions even begin. The Bard PowerPort MDL required key depositions to be completed before April 4, 2025, with discovery plans due April 7, 2025, illustrating how courts attempt to impose structure on these sprawling document reviews.
The Bellwether Selection Process and Its Impact on Discovery Timelines
Bellwether trials serve as test cases that help both sides evaluate the strength of their positions and often drive settlement negotiations. However, selecting and preparing these representative cases adds substantial time to the overall litigation. In the Hair Relaxer mdl, case selections are due April 30, 2025, with cases narrowed to ten by March 2026 and trials expected in early 2027. This two-year gap between case selection and trial reflects the intensive preparation required for cases that will effectively set the tone for thousands of similar claims. The bellwether process requires parties to identify cases that fairly represent the range of injuries, defendants, and factual circumstances across the broader litigation.
This negotiation itself can be contentious, as each side wants cases that favor their position. Courts typically require multiple bellwether trials to account for different injury types or product variants””the GLP-1 MDL has scheduled subsequent trials for March 3 and May 11, 2026, following the January 12, 2026 initial trial. However, bellwether results do not always predict ultimate outcomes. If early trials go poorly for plaintiffs, defendants may become less willing to offer meaningful settlements. Conversely, substantial plaintiff verdicts can accelerate negotiations but may also prompt appeals that delay resolution further. Claimants should understand that even after bellwether trials conclude, their individual cases may require additional years before resolution.
Current MDL Discovery Schedules: A Comparative Analysis
Examining active MDLs reveals significant variation in how courts structure discovery timelines. The Depo-Provera MDL began discovery on March 27, 2025, with evidence gathering scheduled to conclude September 23, 2025″”a relatively compact six-month window. Expert witness disputes must be resolved by February 10, 2026, positioning the case for initial trials in late 2026 or early 2027. This aggressive schedule suggests the court anticipates a manageable document volume and plaintiff count. The Hair Relaxer MDL operates on a longer timeline, with bellwether discovery completion set for February 16, 2026, and trials not expected until early 2027.
This extended schedule reflects the complexity of establishing causation between hair relaxer products and various cancers, requiring detailed expert analysis of chemical exposure levels and epidemiological data. The case also involves multiple defendants, each producing separate document sets. The Uber Sexual Assault MDL demonstrates how non-pharmaceutical mass torts can proceed more quickly. With case-specific fact discovery closing by July 16, 2025, expert reports exchanged by August 8, 2025, and the first bellwether trial scheduled for December 8, 2025, this litigation moves at a notably faster pace. The difference reflects the nature of the evidence””individual incident reports and corporate safety policies rather than years of clinical trial data and internal research documents.
What Claimants Should Expect During the Discovery Phase
For individual plaintiffs, discovery involves both contributing to the collective litigation and potentially participating in case-specific fact-finding. Claimants may need to provide medical records, answer written interrogatories, sit for depositions, and authorize release of employment or insurance records. This process requires patience and consistent communication with counsel, as document requests may arrive at various stages over months or years. The trade-off in mass tort litigation is efficiency versus individual attention. While MDL consolidation allows plaintiffs to pool resources and benefit from shared discovery, it also means individual cases may sit dormant while bellwether cases proceed.
A plaintiff whose case is not selected for bellwether treatment might wait years while test trials and appeals play out, even if their evidence is strong. Conversely, if bellwether results prompt a global settlement, that same plaintiff might resolve their claim without ever testifying. Claimants should also understand that discovery can reveal information that weakens their case. Medical record reviews might uncover alternative causes for alleged injuries, or employment records might contradict claimed damages. Defense experts will scrutinize every aspect of plaintiff claims, and discovery is when that scrutiny becomes most intense. Plaintiffs should be prepared to work closely with their attorneys to address potential weaknesses early in the process.
Common Delays and Obstacles in Mass Tort Discovery
Discovery disputes frequently extend mass tort timelines beyond initial projections. Defendants may resist producing certain documents by claiming privilege, trade secret protection, or undue burden. These objections require judicial resolution through motions practice, adding weeks or months to the schedule. In large MDLs, dozens of discovery disputes may require court intervention before the parties can proceed to depositions. Expert witness challenges present another common obstacle. Defendants routinely file Daubert motions seeking to exclude plaintiff experts, arguing their methodologies are unreliable or their opinions lack adequate foundation.
The GLP-1 MDL’s May 2025 evidentiary hearing likely addresses such challenges. If courts exclude key experts, plaintiffs may need additional time to retain new witnesses and develop alternative scientific theories. Coordination among plaintiffs can also create friction. With different law firms representing thousands of claimants, disagreements about litigation strategy, resource allocation, and settlement authority can slow progress. Leadership structures in MDLs help manage these tensions, but internal plaintiff disputes occasionally spill into public view and complicate negotiations. Defendants may exploit these divisions to delay proceedings or extract more favorable terms.
Post-Settlement Timelines and Final Resolution
Even after parties announce a settlement, distribution to individual claimants typically requires an additional six to twelve months or longer. Settlement administrators must verify eligibility, review medical documentation, apply allocation formulas, and process claims for thousands of plaintiffs. The 3M Combat Arms settlement, despite its $6.01 billion value, required extensive administration to distribute funds among nearly 260,000 claimants according to injury severity and other factors.
Claimants should budget for this final phase when assessing overall timelines. A case that settles in 2026 may not result in actual payment until 2027 or later. Some settlements also include provisions for appeals or opt-outs that can further delay distribution. Understanding this reality helps plaintiffs plan financially and avoid frustration when announced settlements do not immediately translate to compensation.
Looking Ahead: Mass Tort Discovery in an Evolving Legal Landscape
Courts and litigants continue experimenting with procedures to manage mass tort discovery more efficiently. Technology-assisted document review, standardized discovery protocols, and specialized case management orders help control timelines in some MDLs. The compressed schedule in the Uber MDL may reflect judicial willingness to impose discipline when case characteristics permit faster resolution.
However, the fundamental tensions in mass tort discovery remain. Defendants have incentives to delay, plaintiffs need comprehensive evidence to prove their claims, and courts must balance efficiency against fairness. As MDLs grow larger and more complex, discovery timelines will likely remain measured in years rather than months for most pharmaceutical and medical device litigation. Claimants entering this process should prepare for a marathon, not a sprint.
Conclusion
Discovery in mass tort litigation has no fixed timeline, with durations ranging from six months in streamlined cases to several years in complex pharmaceutical MDLs. Current examples illustrate this range: the Depo-Provera MDL anticipates six months of evidence gathering, while the Hair Relaxer MDL’s discovery phase spans nearly two years. Factors including plaintiff count, document volume, scientific complexity, and the bellwether selection process all influence how long parties will spend gathering evidence before trials can begin.
For claimants, understanding these timelines helps set realistic expectations and informs decisions about participating in mass tort litigation. While the process can feel frustratingly slow, the discovery phase serves essential functions””establishing the factual record, identifying the strongest cases for trial, and creating pressure for meaningful settlement negotiations. Working with experienced counsel and remaining patient through the process offers the best path toward eventual resolution.